Close this search box.

Heart disease patients, providers, caregivers and stakeholders agree: Health plan policies that delay access to life-saving medication are unacceptable.  

The Partnership to Advance Cardiovascular Health’s recent survey revealed strong opinions about the danger of prior authorization and the risk associated with step therapy.  The 350 respondents agreed that:

Respondents overwhelmingly agreed that physicians, not health insurers, should decide which prescription medications their patients need (97%).  

In addition to sharing their opinions about medication access, those polled responded to questions about treatment options.  Their answers underscore why they perceive access barriers as particularly dangerous. Survey participants recognized that changing diet and exercise patterns isn’t enough to lower some people’s LDL cholesterol to a safe level (80%).  This is especially important as high LDL cholesterol doubles one’s risk of having heart disease.

On the issue of treatment, respondents also reported that:

Just as participants recognize the value of condition-specific treatment, they agree that health insurers take a one-size-fits-all approach to cardiovascular health (79%).

The Partnership to Advance Cardiovascular Health previously released national and state-specific report cards highlighting the extent to which health plans reject claims for innovative cholesterol-lowering medication known as PCSK9 inhibitors.  

To learn more, read the Partnership to Advance Cardiovascular Health’s full survey results.

Leave a Reply

Your email address will not be published. Required fields are marked *